Cargando…

Epidemiology and Transmitted HIV-1 Drug Resistance among Treatment-Naïve Individuals in Israel, 2010–2018

Despite the low prevalence of HIV-1 in Israel, continuous waves of immigration may have impacted the local epidemic. We characterized all people diagnosed with HIV-1 in Israel in 2010–2018. The demographics and clinical data of all individuals (n = 3639) newly diagnosed with HIV-1 were retrieved. Su...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Tali, Zuckerman, Neta S., Halperin, Tami, Chemtob, Daniel, Levy, Itzchak, Elbirt, Daniel, Shachar, Eduardo, Olshtain-Pops, Karen, Elinav, Hila, Chowers, Michal, Itsomin, Valery, Riesenberg, Klaris, Wax, Marina, Shirazi, Rachel, Gozlan, Yael, Matus, Natasha, Girshengorn, Shirley, Marom, Rotem, Mendelson, Ella, Turner, Dan, Mor, Orna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779053/
https://www.ncbi.nlm.nih.gov/pubmed/35062274
http://dx.doi.org/10.3390/v14010071
_version_ 1784637476811309056
author Wagner, Tali
Zuckerman, Neta S.
Halperin, Tami
Chemtob, Daniel
Levy, Itzchak
Elbirt, Daniel
Shachar, Eduardo
Olshtain-Pops, Karen
Elinav, Hila
Chowers, Michal
Itsomin, Valery
Riesenberg, Klaris
Wax, Marina
Shirazi, Rachel
Gozlan, Yael
Matus, Natasha
Girshengorn, Shirley
Marom, Rotem
Mendelson, Ella
Turner, Dan
Mor, Orna
author_facet Wagner, Tali
Zuckerman, Neta S.
Halperin, Tami
Chemtob, Daniel
Levy, Itzchak
Elbirt, Daniel
Shachar, Eduardo
Olshtain-Pops, Karen
Elinav, Hila
Chowers, Michal
Itsomin, Valery
Riesenberg, Klaris
Wax, Marina
Shirazi, Rachel
Gozlan, Yael
Matus, Natasha
Girshengorn, Shirley
Marom, Rotem
Mendelson, Ella
Turner, Dan
Mor, Orna
author_sort Wagner, Tali
collection PubMed
description Despite the low prevalence of HIV-1 in Israel, continuous waves of immigration may have impacted the local epidemic. We characterized all people diagnosed with HIV-1 in Israel in 2010–2018. The demographics and clinical data of all individuals (n = 3639) newly diagnosed with HIV-1 were retrieved. Subtypes, transmitted drug-resistance mutations (TDRM), and phylogenetic relations, were determined in >50% of them. In 39.1%, HIV-1 transmission was through heterosexual contact; 34.3% were men who have sex with men (MSM); and 10.4% were people who inject drugs. Many (>65%) were immigrants. Israeli-born individuals were mostly (78.3%) MSM, whereas only 9% of those born in Sub-Saharan Africa (SSA), Eastern Europe and Central Asia (EEU/CA), were MSM. The proportion of individuals from SSA decreased through the years 2010–2018 (21.1% in 2010–2012; 16.8% in 2016–2018) whereas those from EEU/CA increased significantly (21% in 2010–2012; 27.8% in 2016–2018, p < 0.001). TDRM were identified in 12.1%; 3.7, 3.3 and 6.6% had protease inhibitors (PI), nucleotide reverse transcriptase inhibitors (NRTI), and non-nucleoside reverse transcriptase inhibitors (NNRTI) TDRM, respectively, with the overall proportion remaining stable in the studied years. None had integrase TDRM. Subtype B was present in 43.9%, subtype A in 25.2% (A6 in 22.8 and A1 in 2.4%) and subtype C in 17.1% of individuals. Most MSM had subtype B. Subtype C carriers formed small clusters (with one unexpected MSM cluster), A1 formed a cluster mainly of locally-born patients with NNRTI mutations, and A6 formed a looser cluster of individuals mainly from EEU. Israelis, <50 years old, carrying A1, had the highest risk for having TDRM. In conclusion, an increase in immigrants from EEU/CA and a decrease in those from SSA characterized the HIV-1 epidemic in 2010–2018. Baseline resistance testing should still be recommended to identify TDRM, and improve surveillance and care.
format Online
Article
Text
id pubmed-8779053
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87790532022-01-22 Epidemiology and Transmitted HIV-1 Drug Resistance among Treatment-Naïve Individuals in Israel, 2010–2018 Wagner, Tali Zuckerman, Neta S. Halperin, Tami Chemtob, Daniel Levy, Itzchak Elbirt, Daniel Shachar, Eduardo Olshtain-Pops, Karen Elinav, Hila Chowers, Michal Itsomin, Valery Riesenberg, Klaris Wax, Marina Shirazi, Rachel Gozlan, Yael Matus, Natasha Girshengorn, Shirley Marom, Rotem Mendelson, Ella Turner, Dan Mor, Orna Viruses Article Despite the low prevalence of HIV-1 in Israel, continuous waves of immigration may have impacted the local epidemic. We characterized all people diagnosed with HIV-1 in Israel in 2010–2018. The demographics and clinical data of all individuals (n = 3639) newly diagnosed with HIV-1 were retrieved. Subtypes, transmitted drug-resistance mutations (TDRM), and phylogenetic relations, were determined in >50% of them. In 39.1%, HIV-1 transmission was through heterosexual contact; 34.3% were men who have sex with men (MSM); and 10.4% were people who inject drugs. Many (>65%) were immigrants. Israeli-born individuals were mostly (78.3%) MSM, whereas only 9% of those born in Sub-Saharan Africa (SSA), Eastern Europe and Central Asia (EEU/CA), were MSM. The proportion of individuals from SSA decreased through the years 2010–2018 (21.1% in 2010–2012; 16.8% in 2016–2018) whereas those from EEU/CA increased significantly (21% in 2010–2012; 27.8% in 2016–2018, p < 0.001). TDRM were identified in 12.1%; 3.7, 3.3 and 6.6% had protease inhibitors (PI), nucleotide reverse transcriptase inhibitors (NRTI), and non-nucleoside reverse transcriptase inhibitors (NNRTI) TDRM, respectively, with the overall proportion remaining stable in the studied years. None had integrase TDRM. Subtype B was present in 43.9%, subtype A in 25.2% (A6 in 22.8 and A1 in 2.4%) and subtype C in 17.1% of individuals. Most MSM had subtype B. Subtype C carriers formed small clusters (with one unexpected MSM cluster), A1 formed a cluster mainly of locally-born patients with NNRTI mutations, and A6 formed a looser cluster of individuals mainly from EEU. Israelis, <50 years old, carrying A1, had the highest risk for having TDRM. In conclusion, an increase in immigrants from EEU/CA and a decrease in those from SSA characterized the HIV-1 epidemic in 2010–2018. Baseline resistance testing should still be recommended to identify TDRM, and improve surveillance and care. MDPI 2021-12-31 /pmc/articles/PMC8779053/ /pubmed/35062274 http://dx.doi.org/10.3390/v14010071 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wagner, Tali
Zuckerman, Neta S.
Halperin, Tami
Chemtob, Daniel
Levy, Itzchak
Elbirt, Daniel
Shachar, Eduardo
Olshtain-Pops, Karen
Elinav, Hila
Chowers, Michal
Itsomin, Valery
Riesenberg, Klaris
Wax, Marina
Shirazi, Rachel
Gozlan, Yael
Matus, Natasha
Girshengorn, Shirley
Marom, Rotem
Mendelson, Ella
Turner, Dan
Mor, Orna
Epidemiology and Transmitted HIV-1 Drug Resistance among Treatment-Naïve Individuals in Israel, 2010–2018
title Epidemiology and Transmitted HIV-1 Drug Resistance among Treatment-Naïve Individuals in Israel, 2010–2018
title_full Epidemiology and Transmitted HIV-1 Drug Resistance among Treatment-Naïve Individuals in Israel, 2010–2018
title_fullStr Epidemiology and Transmitted HIV-1 Drug Resistance among Treatment-Naïve Individuals in Israel, 2010–2018
title_full_unstemmed Epidemiology and Transmitted HIV-1 Drug Resistance among Treatment-Naïve Individuals in Israel, 2010–2018
title_short Epidemiology and Transmitted HIV-1 Drug Resistance among Treatment-Naïve Individuals in Israel, 2010–2018
title_sort epidemiology and transmitted hiv-1 drug resistance among treatment-naïve individuals in israel, 2010–2018
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779053/
https://www.ncbi.nlm.nih.gov/pubmed/35062274
http://dx.doi.org/10.3390/v14010071
work_keys_str_mv AT wagnertali epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT zuckermannetas epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT halperintami epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT chemtobdaniel epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT levyitzchak epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT elbirtdaniel epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT shachareduardo epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT olshtainpopskaren epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT elinavhila epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT chowersmichal epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT itsominvalery epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT riesenbergklaris epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT waxmarina epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT shirazirachel epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT gozlanyael epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT matusnatasha epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT girshengornshirley epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT maromrotem epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT mendelsonella epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT turnerdan epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018
AT mororna epidemiologyandtransmittedhiv1drugresistanceamongtreatmentnaiveindividualsinisrael20102018